Jackson Square Partners’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-98,062
Closed -$9.06M 80
2024
Q2
$9.06M Sell
98,062
-11,318
-10% -$1M 0.55% 44
2024
Q1
$10.5M Sell
109,380
-8,533
-7% -$717K 0.43% 46
2023
Q4
$8.99M Sell
117,913
-16,594
-12% -$1.15M 0.29% 47
2023
Q3
$9.32M Sell
134,507
-2,350
-2% -$189K 0.31% 45
2023
Q2
$12.9M Sell
136,857
-43,523
-24% -$3.78M 0.38% 40
2023
Q1
$14.9M Sell
180,380
-79,209
-31% -$6.23M 0.4% 34
2022
Q4
$19.4M Sell
259,589
-40,433
-13% -$3.12M 0.52% 35
2022
Q3
$24.8M Sell
300,022
-67,637
-18% -$6.51M 0.65% 34
2022
Q2
$35M Sell
367,659
-1,526,984
-81% -$158M 0.82% 32
2022
Q1
$223M Sell
1,894,643
-59,027
-3% -$6.62M 2.21% 9
2021
Q4
$253M Sell
1,953,670
-1,132,598
-37% -$132M 2.13% 15
2021
Q3
$349M Sell
3,086,268
-375,184
-11% -$42.8M 2.22% 14
2021
Q2
$359M Sell
3,461,452
-510,646
-13% -$48.1M 2.05% 14
2021
Q1
$332M Sell
3,972,098
-2,860,772
-42% -$242M 1.89% 15
2020
Q4
$623M Buy
6,832,870
+816,051
+14% +$67.7M 2.49% 11
2020
Q3
$480M Buy
+6,016,819
New +$469M 2.25% 13

Other funds holding EW

Jackson Square Partners's EW Position: Q3 2024 in Review

Jackson Square Partners sold out of Edwards Lifesciences (EW) in Q3 2024, closing a stake of 98,062 shares — an estimated $9.06M sold.

Jackson Square Partners first reported a position in EW in Q3 2020 and held it in 16 quarters. The position peaked at $623M in Q4 2020. 1,193 funds tracked by Wall St. Rank hold EW as of Q3 2024.

  • Jackson Square Partners reported no remaining Edwards Lifesciences position as of Q3 2024 after selling out during the quarter.
  • Jackson Square Partners sold 98,062 Edwards Lifesciences shares in Q3 2024, an estimated $9.06M.
  • Jackson Square Partners first reported a position in Edwards Lifesciences in Q3 2020 and held it in 16 quarters.
  • Jackson Square Partners's Edwards Lifesciences position peaked at $623M in Q4 2020.
  • 1,193 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2024.

Based on Jackson Square Partners's 13F filing for Q3 2024, filed 13 Nov 2024.